SELDI-TOF mass spectrometry for cancer biomarker discovery and serum proteomic diagnostics

Pharmacogenomics

Volumn 6, Issue 6, 2005, Pages 647-653

  Simpkins, Fiona ^a   Czechowicz, Josephine A ^a   Liotta, Lance ^a,b   Kohn, Elise C ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Biomarker; Mass spectrometry; Proteomics; SELDI TOF

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; CA 125 ANTIGEN; GLOBIN; PROTEOLIPID PROTEIN;

AMINO ACID SEQUENCE; ANTIGEN DETECTION; ARTICLE; BIOINFORMATICS; BLOOD ANALYSIS; CANCER DIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ECHOGRAPHY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EXPERT; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

HUMANS; MASS SPECTROMETRY; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 25144519779     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.6.6.647     Document Type: Article

References (51)

1. Anderson GR, Brenner BM: Molecular markers in colorectal cancer. Lancet 359(9302), 183-184 (2002).
2. Ward JB Jr, Henderson RE: Identification of needs in biomarker research. Environ. Health Perspect. 104(Suppl. 5), 895-900 (1996).
3. Bast RC Jr, King TL, St John E et al.: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N. Engl. J. Med. 309(15), 883-887 (1983).
4. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA: Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol. Oncol. 82(1), 40-48 (2001).
5. Menon U, Jacobs IJ: Recent developments in ovarian cancer screening. Curr. Opin. Obstet. Gynecol. 12(1), 39-42 (2000).
6. Niloff JM, Klug TL, Schaetzl E, Zurawski VR Jr, Knapp RC, Bast RC Jr: Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am. J. Obstet. Gynecol. 148(8), 1057-1058 (1984).
7. Ozols RF, Rubin SC, Thomas GM, Robboy SJ: Epithelial ovarian cancer. In: Principles and Practice of Gynecological Oncology. Hoskins WJ, Perez CA, Young RC (Eds), Lippincott Williams and Wilkins, Philadelphia, PA, USA (2001).
8. Skates SJ, Xu FJ, Yu YH et al.: Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer 76(Suppl. 10), 2004-2010 (1995).
9. Anderson NL, Polanski M, Pieper R et al.: The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol. Cell Proteomics 3(4), 311-326 (2004).
10. Tirumalai RS, Chan KC, Prieto DA, Issaq HJ, Conrads TP, Veenstra TD: Characterization of the low molecular weight human serum proteome. Mol. Cell Proteomics 2(10), 1096-1103 (2003).
11. Kantor AB: Comprehensive phenotyping and biological marker discovery. Dis. Markers 18(2), 91-97 (2002).
12. Petricoin EF, Ardekani AM, Hitt BA et al.: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
13. Petricoin EF 3rd, Ornstein DK, Paweletz CP et al.: Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst. 94(20), 1576-1578 (2002).
14. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48(8), 1296-1304 (2002).
15. Conrads TP, Zhou M, Petricoin EF 3rd, Liotta L, Veenstra TD: Cancer diagnosis using proteomic patterns. Expert Rev. Mol. Diagn. 3(4), 411-420 (2003).
16. Hingorani SR, Tuveson DA: In search of an early warning system for pancreatic cancer. Cancer Biol. Ther. 2(1), 84-86 (2003).
17. Merchant M, Weinberger SR: Recent advancements in surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Electrophoresis 21(6), 1164-1177 (2000).
18. Petricoin EF, Liotta LA: SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 15(1), 24-30 (2004).
19. Boguski MS, McIntosh MW: Biomedical informatics for proteomics. Nature 422(6928), 233-237 (2003).
20. Conrads TP, Fusaro VA, Ross S et al.: High-resolution serum proteomic features for ovarian cancer detection. Endocr. Relat. Cancer 11(2), 163-178 (2004).
21. DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell JR Jr: Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol. Oncol. 65(3), 408-414 (1997).
22. van Nagell JR Jr, Gallion HH, Pavlik EJ, DePriest PD: Ovarian cancer screening. Cancer 76(Suppl. 10), 2086-2091 (1995).
23. Vlahou A, Schorge JO, Gregory BW, Coleman RL: Diagnosis of ovarian cancer using decision tree classification of mass spectral data. J. Biomed. Biotechnol. (5), 308-314 (2003).
24. Yu Y, Chen S, Wang LS et al.: Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization-based decision tree classification. Oncology 68(1), 79-86 (2005).
25. Yu JS, Ongarello S, Fiedler R et al.: Ovarian cancer identification based on dimensionality reduction for high-throughput mass spectrometry data. Bioinformatics 21(10), 2200-2209 (2005).
26. Liu W, Guan M, Wu D et al.: Using tree analysis pattern and SELDI-TOF-MS to discriminate transitional cell carcinoma of the bladder cancer from noncancer patients. Eur. Urol. 47(4), 456-462 (2005).
27. Fung ET, Yip TT, Lomas L et al.: Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int. J. Cancer 115(5), 783-789 (2005).
28. Adam BL, Qu Y, Davis JW et al.: Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res. 62(13), 3609-3614 (2002).
29. Koopmann J, Zhang Z, White N et al.: Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin. Cancer Res. 10(3), 860-868 (2004).
30. Qu Y, Adam BL, Yasui Y et al.: Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin. Chem. 48(10), 1835-1843 (2002).
31. Yasui Y, Pepe M, Thompson ML et al.: A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics 4(3), 449-463 (2003).
32. Yasui Y, McLerran D, Adam BL, Winget M, Thornquist M, Feng Z: An automated peak identification/calibration procedure for high-dimensional protein measures from mass spectrometers. J. Biomed. Biotechnol. 4, 242-248 (2003).
33. Semmes OJ, Feng Z, Adam BL et al.: Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin. Chem. 51(1), 102-112 (2005).
34. Melle C, Osterloh D, Ernst G, Schimmel B, Bleul A, von Eggeling F: Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry. Int. J. Mol. Med. 16(1), 11-17 (2005).
35. Marshall FF: Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid α in renal cancer patients. J. Urol. 173(6), 1919-1920 (2005).
36. Zhu XD, Zhang WH, Li CL, Xu Y, Liang WJ, Tien P: New serum biomarkers for detection of HBV-induced liver cirrhosis using SELDI protein chip technology. World J. Gastroenterol. 10(16), 2327-2329 (2004).
37. Le L, Chi K, Tyldesley S et al.: Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin. Chem. 51(4), 695-707 (2005).
38. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB: Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol. Cell Biol. 22(7), 2099-2110 (2002).
39. Sutphen R, Xu Y, Wilbanks GD et al.: Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 13(7), 1185-1191 (2004).
40. Carter D, Douglass JF, Cornellison CD et al.: Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 41(21), 6714-6722 (2002).
41. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, Bing-Gen R: Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 3(4), 433-439 (2003).
42. Diamandis EP: Proteomic patterns in serum and identification of ovarian cancer. Lancet 360(9327), 170; author reply 170-171 (2002).
43. Baggerly KA, Morris JS, Coombes KR: Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20(5), 777-785 (2004).
44. Baggerly KA, Morris JS, Edmonson SR, Coombes KR: Signal in noise: evaluating reported reproducibility of serum proteomic tests for ovarian cancer. J. Natl Cancer Inst. 97(4), 307-309 (2005).
45. Sorace JM, Zhan M: A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics 4(1), 24 (2003).
46. White CN, Zhang Z, Chan DW: Quality control for SELDI analysis. Clin. Chem. Lab. Med. 43(2), 125-126 (2005).
47. McIntosh MW, Drescher C, Karlan B et al.: Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol. Oncol. 95(1), 9-15 (2004).
48. Hellstrom I, Raycraft J, Hayden-Ledbetter M et al.: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 63(13), 3695-3700 (2003).
49. Zhang Z, Bast RC Jr, Yu Y et al.: Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 64(16), 5882-5890 (2004).
50. Blume-Jensen P, Hunter T: Oncogenic kinase signaling. Nature 411(6835), 355-365 (2001).
51. Celis JE, Gromov P: Proteomics in translational cancer research: toward an integrated approach. Cancer Cell 3(1), 9-15 (2003).